Monopar Therapeutics (MNPR) Long-Term Deferred Tax (2022 - 2023)
Monopar Therapeutics' (MNPR) quarterly Long-Term Deferred Tax came in at $13.3 million in Q4 2023, up 19.07% year-on-year from $11.1 million in Q4 2022, and up 19.07% quarter-over-quarter from $11.1 million in Q4 2022.
Monopar Therapeutics (MNPR) Long-Term Deferred Tax (2022 - 2023) Analysis & Trends
Monopar Therapeutics has disclosed Long-Term Deferred Tax across 2 years of filings, most recently posting $13.3 million for Q4 2023.
- Long-Term Deferred Tax for Q4 2023 came in at $13.3 million, up 19.07% year-over-year; the trailing twelve-month figure through Dec 2023 was $13.3 million (up 19.07% YoY), and the FY2023 annual result was $13.3 million, up 19.07% from the prior year.
- Long-Term Deferred Tax came in at $13.3 million for Q4 2023 at Monopar Therapeutics, up from $11.1 million in the prior quarter.
- In the past five years, Long-Term Deferred Tax ranged from a high of $13.3 million in Q4 2023 to a low of $11.1 million in Q4 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - |
| 10 | Monopar Therapeutics | 441.25 Mn | 441.25 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 13.27 Mn |
| Dec 31, 2022 | 11.14 Mn |